StreetInsider.com News Articles

Form PRE 14C CALLAN JMB INC. For: Nov 02

Mon, 02 Nov 2026 08:15:00 -0500

si-local-file:///var/storage/secattach/20261102/27270202.html

Callan JMB receives oral thin-film production line from RDT

Mon, 02 Nov 2026 08:01:46 -0500

Callan JMB, Inc. (NASDAQ: CJMB) announced it has received a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics Corp. for installation at its facility in Spring Branch, Texas.

According to a company statement, the equipment delivery marks an entry into U.S.-based manufacturing of fast-dissolving oral thin-film products for pharmaceutical, nutraceutical, and government healthcare applications. The production line is not yet operational and must undergo equipment qualification before commercial use.

The company projects the platform could generate up to $15 million in revenue during the first 18 months of operation following successful qualification, though the figure is subject to risks including customer

Callan JMB Announces Arrival of Rapid Dose Therapeutics’ QuickStrip™, Resulting in $15 Million in Projected Revenue Over the Next 18 months

Mon, 02 Nov 2026 08:00:00 -0500

Milestone advances Callan JMB’s domestic pharmaceutical manufacturing strategy and is expected to create a new high-margin healthcare manufacturing revenue stream at their Texas facility.

SPRING BRANCH, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Callan JMB, Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), a diversified healthcare logistics, preparedness, and critical infrastructure company, today announced that it has received a complete QuickStrip^™ oral thin-film production line from Rapid Dose Therapeutics Corp. (“RDT”) for installation at the Company’s facility in Texas.

The arrival of the manufacturing system completes another significant step in

Callan JMB Announces Arrival of Rapid Dose Therapeutics’ QuickStrip™, Resulting in $15 Million in Projected Revenue Over the Next 18 months

Mon, 02 Nov 2026 08:00:00 -0500

Milestone advances Callan JMB’s domestic pharmaceutical manufacturing strategy and is expected to create a new high-margin healthcare manufacturing revenue stream at their Texas facility.

The arrival of the manufacturing system completes another significant step in

Form EFFECT CALLAN JMB INC.

Mon, 02 Nov 2026 06:06:00 -0500

si-local-file:///var/storage/secattach/20261102/27268933.html

Callan JMB to break ground on $16M IV bag plant in Alabama

Thu, 22 Oct 2026 08:04:36 -0500

Callan JMB Inc. (NASDAQ: CJMB) plans to break ground before the end of October on an intravenous bag manufacturing and distribution facility at the Atlas Complex in Marion, Alabama, according to a press release from the company.

The $16 million facility will be funded by a third party through a partnership the company describes as non-dilutive and non-interest-bearing, meaning it will not add debt to Callan JMB's balance sheet or dilute existing shareholders.

The company received formal blueprint approval ahead of the planned groundbreaking. The facility is planned within the Marion 9 Biomanufacturing Center at the Atlas Complex and is part of

Callan JMB to Break Ground on IV Bag Manufacturing Facility Fully Funded by Non-Dilutive and Non-Interest-Bearing Third-Party Partnership

Thu, 22 Oct 2026 08:00:00 -0500

The non-dilutive $16 million capital investment from a third party for Atlas Complex construction advances Callan JMB’s pharmaceutical manufacturing strategy and strengthens its role in U.S. healthcare supply-chain preparedness

SPRING BRANCH, Texas, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), a diversified preparedness, logistics, and critical-infrastructure company, today is providing shareholders with a timeline to break ground on an intravenous (IV) bag manufacturing and distribution facility at the Atlas Complex in Marion, Alabama. The $16 million facility will be fully funded by a third party through a

Callan JMB to Break Ground on IV Bag Manufacturing Facility Fully Funded by Non-Dilutive and Non-Interest-Bearing Third-Party Partnership

Thu, 22 Oct 2026 08:00:00 -0500

Rapid Dose Therapeutics Ships QuickStrip(TM) Production Line to Callan JMB's Texas cGMP Facility

Wed, 21 Oct 2026 09:16:00 -0500

Burlington, Ontario--(Newsfile Corp. - October 21, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company specializing in oral thin-film drug delivery technology, today announced that it has shipped a complete QuickStrip™ production line to Callan JMB Inc. (NASDAQ: CJMB) ("Callan JMB") for planned installation at its cGMP facility in Texas, United States.

The shipment advances the collaboration outlined in Callan JMB's November 13, 2025, announcement, which described a preliminary agreement to install oral thin-film manufacturing equipment at its Texas facility while the companies negotiate operational arrangements.